3 news items
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
TEVA
8 May 24
and trade control laws; environmental risks; and the impact of sustainability issues;
the impact
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
TEVA
8 May 24
the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
TEVA
2 May 24
, Teva's renewed sustainability strategy, is a continuation of the Company's environmental, social and governance (ESG
- Prev
- 1
- Next